BIOX
Get informed when a big investor buys or sells
+ FollowOvervalued by 3221.5% based on the discounted cash flow analysis.
| Market cap | $22.14 Million |
|---|---|
| Enterprise Value | $250.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.82 |
| Beta | 0.42 |
| Outstanding Shares | 63,600,000 |
| P/E Ratio | -0.09 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 0.09 |
| Price to Book Ratio | 0.34 |
| Enterprise Value to Revenue | 0.95 |
| Enterprise Value to EBIT | -20.06 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.97 |
| Debt to Equity | 3.59 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 30,000▲ 152.10% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.84%▼ 13.73% |
|---|---|
| Total Invested | $186,075▼ 95.47% |
| Investors Holding | 4▼ 27.00% |
No data